To include your compound in the COVID-19 Resource Center, submit it here.

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Public debut for ENT company signals continued strength among new listings in a season of volatility

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and throat diseases company priced late Thursday in the final hours of a month in

Read the full 490 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers